Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DX9OCI
|
||||
| Drug Name |
N-(4-(chlorodifluoromethoxy)phenyl)-5-(1-methyl-4-(pyridin-4-ylmethylamino)-1H-imidazol-5-yl)-1,3,4-oxadiazol-2-amine
|
||||
| Synonyms |
CHEMBL205884
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C19H16ClF2N7O2
|
||||
| Canonical SMILES |
Cn1cnc(NCc2ccncc2)c1c3oc(Nc4ccc(OC(F)(F)Cl)cc4)nn3
|
||||
| InChI |
InChI=1S/C19H16ClF2N7O2/c1-29-11-25-16(24-10-12-6-8-23-9-7-12)15(29)17-27-28-18(30-17)26-13-2-4-14(5-3-13)31-19(20,21)22/h2-9,11,24H,10H2,1H3,(H,26,28)
|
||||
| InChIKey |
OXKXXXGUZPQGGS-UHFFFAOYSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
| Vascular endothelial growth factor receptor 1 | Target Info | [1587926] | |||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| VEGF signaling pathway | |||||
| Focal adhesion | |||||
| Proteoglycans in cancerhsa04014:Ras signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network | |||||
| S1P3 pathway | |||||
| VEGFR1 specific signals | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.